Acumen Pharmaceuticals (ABOS) Total Non-Current Liabilities (2023 - 2025)

Acumen Pharmaceuticals (ABOS) has 3 years of Total Non-Current Liabilities data on file, last reported at $52.4 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 8.11% year-over-year to $52.4 million; the trailing twelve-month figure through Dec 2025 stood at $52.4 million (down 8.11% YoY), and the FY2025 full-year result was $52.4 million, down 8.11% from the prior year.
• Total Non-Current Liabilities climbed to $52.4 million in Q4 2025, from $49.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $57.0 million in Q4 2024 to a low of $42.9 million in Q4 2023.
• A 3-year average of $50.8 million and a median of $50.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 33.03% in 2024 and slipped 8.11% in 2025, its largest moves.
• Tracing ABOS's Total Non-Current Liabilities over 3 years: stood at $42.9 million in 2023, then jumped by 33.03% to $57.0 million in 2024, then dropped by 8.11% to $52.4 million in 2025.
• Business Quant data shows ABOS's Total Non-Current Liabilities at $52.4 million in Q4 2025, $49.0 million in Q3 2025, and $54.7 million in Q2 2025.